SemBioSys to Proceed With Abbreviated Regulatory Path for Plant-Produced Insulin After Meeting With the FDA
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Shortens Clinical Timelines by Eliminating Duplicative Insulin Trials TSX symbol: SBS SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical ...